Awad, Mark M.

JASPER: Phase 2 trial of first‐line niraparib plus pembrolizumab in patients with advanced non–small cell lung cancer

Ramalingam, S. S., Thara, E., Awad, M. M., Dowlati, A., Haque, B., Stinchcombe, T. E., Dy, G. K., Spigel, D. R., Lu, S., Iyer Singh, N., et al. (2022) · Cancer

Cancer Immunotherapy and BiomarkersPARP inhibition in cancer therapy

Cited by 75

Safety and efficacy of immune checkpoint inhibitors in patients with non-small cell lung cancer and hepatitis B or hepatitis C infection

Pertejo-Fernandez, A., Ricciuti, B., Hammond, S. P., Marty, F. M., Recondo, G., Rangachari, D., Costa, D. B., & Awad, M. M. (2020) · Lung Cancer

Cancer Immunotherapy and BiomarkersLung Cancer Treatments and Mutations

Cited by 46

Programmed Death Ligand-1 and Tumor Mutation Burden Testing of Patients With Lung Cancer for Selection of Immune Checkpoint Inhibitor Therapies: Guideline From the College of American Pathologists, Association for Molecular Pathology, International Association for the Study of Lung Cancer, Pulmonary Pathology Society, and LUNGevity Foundation

Sholl, L. M., Awad, M., Basu Roy, U., Beasley, M. B., Cartun, R. W., Hwang, D. M., Kalemkerian, G., Lopez-Rios, F., Mino-Kenudson, M., Paintal, A., et al. (2024) · Archives of Pathology & Laboratory Medicine

Cancer Immunotherapy and BiomarkersLung Cancer Treatments and Mutations

Cited by 38

690P Ifinatamab deruxtecan (I-DXd; DS-7300) in patients with advanced solid tumors: Updated clinical and biomarker results from a phase I/II study

Patel, M. R., Doi, T., Koyama, T., Falchook, G. S., Friedman, C. F., Piha-Paul, S. A., Gutierrez, M., Awad, M. M., Mattour, A. H., Satoh, T., et al. (2023) · Annals of Oncology

Cancer Immunotherapy and BiomarkersMonoclonal and Polyclonal Antibodies Research

Cited by 33

Abstract LB002: Mechanisms of acquired resistance to KRAS G12C inhibition in cancer

Awad, M., Liu, S., Arbour, K., Zhu, V., Johnson, M., Heist, R., Patil, T., Riely, G., Jacobson, J., Dilly, J., et al. (2021) · Cancer Research

Lung Cancer Treatments and MutationsProtein Kinase Regulation and GTPase Signaling

Cited by 12

A phase Ib study of abemaciclib in combination with pembrolizumab for patients (pts) with stage IV Kirsten rat sarcoma mutant (KRAS-mut) or squamous non-small cell lung cancer (NSCLC) (NCT02779751): Interim results.

Pujol, J.-L., Vansteenkiste, J. F., Paz-Ares, L. G., Gregorc, V., Mazieres, J., Awad, M. M., Janne, P. A., Chisamore, M. J., Hossain, A., Chen, Y., et al. (2020) · Journal of Clinical Oncology

Lung Cancer Treatments and MutationsCancer Immunotherapy and Biomarkers

Cited by 7